-
![Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors](/abs-image/US/2017/03/21/US09598423B2/abs.jpg.150x150.jpg)
1.发明授权公开(公告)号：US09598423B2
公开(公告)日：2017-03-21
申请号：US15034217
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: A61K31/498 , C07D487/04 , C07D491/147 , C07D487/10 , C07D491/20 , C07D487/20 , C07D519/00
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US11166959B2
公开(公告)日：2021-11-09
申请号：US16761449
申请日：2018-11-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Erika M. V. Araujo , Yan Chen , Bireshwar Dasgupta , Andrew P. Degnan , Matthew D. Hill , Godwin Kwame Kumi , Harold A. Mastalerz , Mark D. Wittman , Bradley C. Pearce , Guifen Zhang
IPC: A61K31/5377 , A61K31/506 , A61P35/00 , A61K45/06 , C07D405/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
公开(公告)号：US09556179B2
公开(公告)日：2017-01-31
申请号：US14653895
申请日：2013-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Dharmpal S. Dodd , Anthony J. Sampognaro , Mark D. Wittman , Selvakumar Kumaravel , Dibakar Mullick , Peiying Liu , Chandrasekhar Reddy Rachamreddy
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
公开(公告)号：US20170137427A1
公开(公告)日：2017-05-18
申请号：US15319028
申请日：2015-06-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Selvakumar Kumaravel , Arul Mozhi Selvan Subbiah Karupplah , Shilpa Holehatti Maheshwarappa , Chandrasekhar Reddy Rachamreddy , Mark D. Wittman
IPC: C07D487/04 , C07D519/00
CPC classification number: A61K31/5025 , C07D487/04 , C07D519/00
Abstract: The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
5.发明申请PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS 有权吡唑取代的咪唑啉作为CASEIN KINASE 1 D / E抑制剂公开(公告)号：US20150344480A1
公开(公告)日：2015-12-03
申请号：US14653878
申请日：2013-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chen Padmakar Dame , Dharmpal s. Dodd , Peiying Liu , Christopher P. Mussari , Mark D. Wittman , Selvakumar Kumaravel , Dibakar Mullick
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
Patent Agency Ranking
6.发明申请NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS 有权新型替代吡唑并吡啶作为CASEIN KINASE 1 D / E抑制剂公开(公告)号：US20150133428A1
公开(公告)日：2015-05-14
申请号：US14541343
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D491/20 , C07D491/147
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
公开(公告)号：US09956220B2
公开(公告)日：2018-05-01
申请号：US15319028
申请日：2015-06-18
Applicant: Bristol-Myers Squibb Company
Inventor： Upender Velaparthi , Selvakumar Kumaravel , Arul Mozhi Selvan Subbiah Karupplah , Shilpa Holehatti Maheshwarappa , Chandrasekhar Reddy Rachamreddy , Mark D. Wittman
IPC: A61K31/5025 , C07D487/04 , C07D519/00
CPC classification number: A61K31/5025 , C07D487/04 , C07D519/00
Abstract: The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
8.发明授权Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors 有权吡唑取代的咪唑并吡嗪作为酪蛋白激酶1 d / e抑制剂公开(公告)号：US09475817B2
公开(公告)日：2016-10-25
申请号：US14653878
申请日：2013-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Dharmpal S. Dodd , Peiying Liu , Christopher P. Mussari , Mark D. Wittman , Selvakumar Kumaravel , Dibakar Mullick
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US20160122358A1
公开(公告)日：2016-05-05
申请号：US14994346
申请日：2016-01-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Subbiah Karuppiah , Subba Reddy Bandreddy , Nagalakshmi Pulicharla , Rajesh Onkardas Bora , Shilpa Maheshwarappa Holehatti , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Kumar Sistla
IPC: C07D487/04 , C07D487/20 , C07D491/20 , C07D487/10 , C07D491/147
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
10.发明授权公开(公告)号：US09273058B2
公开(公告)日：2016-03-01
申请号：US14541343
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , A61K31/4985 , A61K31/499 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P19/02
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.043 seconds)
